Long-term safety and efficacy of nevirapine-based approaches in HIV type 1-infected patients

AIDS Research and Human Retroviruses
Anna BonjochBonaventura Clotet

Abstract

Using a multicenter, cross-sectional, observation study, the long-term safety, metabolic profile, and viral efficacy of nevirapine (NVP)-based approaches in HIV-1-infected patients treated for at least 2 years were assessed. For 4 months, all consecutive HIV-1-infected patients who had been receiving an NVP-containing regimen for at least 2 years were recruited. A total of 613 patients were included with a median follow-up period of 43 months (IQR: 31-51). At baseline, 24.5% (150 patients) were treatment naive, 41.5% (254 patients) switched for simplification purposes, and 34% (209 patients) were failing HAART. Increases by five times or more in AST/ALT values were observed in fewer than 2% of patients. Only 5.7% of all adverse events reported during the investigation were attributable to NVP. The percentage of patients with normal HDL cholesterol levels rose from 17.7% at baseline to 35.4% at the last visit. At the latest time point available for analysis, 76% of naive and 74% of those who had switched had HIV-1 RNA loads of <50 copies/ml, while 59% of salvage patients achieved this level of viral suppression. Factors associated with viral suppression at the latest visit were adequate adherence (OR: 2.58, 95% CI: 0.85-7.78, p ...Continue Reading

References

Sep 2, 2000·Journal of Acquired Immune Deficiency Syndromes : JAIDS·M PuotiG Carosi
Dec 19, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·S J Bersoff-MatchaL M Mundy
Jan 12, 2002·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Mark S SulkowskiRichard D Moore
Jan 18, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Eugenia NegredoBonaventura Clotet
Jan 25, 2002·AIDS·Daniel González de RequenaVincent Soriano
Mar 28, 2002·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Ron PalmonDouglas T Dieterich
Aug 9, 2002·AIDS Research and Human Retroviruses·Thomas F KresinaLaura W Cheever
Nov 1, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·F BonnetUNKNOWN French Aquitaine Cohort. Groupe d'Epidémiologie Clinique du SIDA en Aquitaine (GECSA)
Jun 12, 2003·Seminars in Liver Disease·Nickolas Kontorinis, Douglas T Dieterich
Sep 12, 2003·The New England Journal of Medicine·Esteban MartínezUNKNOWN Nevirapine, Efavirenz, and Abacavir (NEFA) Study Team
Oct 18, 2003·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Robert L Murphy
Oct 18, 2003·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Joep M A Lange
May 6, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Jean-Jacques ParientiRenaud Verdon

❮ Previous
Next ❯

Citations

Aug 1, 2009·AIDS Patient Care and STDs·Mark J Atkinson, Jeffrey J Petrozzino
May 23, 2009·HIV Medicine·Manuela ColafigliA De Luca
Aug 28, 2012·Pharmacogenomics·Rebecca PavlosElizabeth Phillips
Feb 18, 2016·Journal of Pharmaceutical Policy and Practice·Francis KalemeeraJohannes Gaeseb
Nov 27, 2007·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Carlo TortiUNKNOWN BHCC Study Group
Jan 8, 2008·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Ellen M TedaldiMary van den Berg-Wolf
Jun 27, 2007·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Roberto Manfredi, Leonardo Calza

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.